GENELUX Corp — Investor Relations & Filings
Genelux Corporation is a clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for patients with aggressive and difficult-to-treat solid tumors. The company's technology is based on a proprietary discovery platform, CHOICE™, which utilizes an engineered vaccinia virus (VACV) as its backbone. This approach creates "off-the-shelf" therapeutics designed to selectively replicate within and kill cancer cells, stimulating a robust, patient-specific anti-tumor immune response. The lead product candidate, Olvi-Vec, is a modified vaccinia virus administered systemically. It is currently being evaluated in a registrational Phase 3 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer. The company is also preparing for a Phase 2 trial in recurrent non-small cell lung cancer.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS - GENELUX Corp (0001231457) (Filer) | 2026-04-29 | English | |
| DEF 14A - GENELUX Corp (0001231457) (Filer) | 2026-04-29 | English | |
| 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | |
| 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | |
| 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | |
| 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 38557262 | ARS - GENELUX Corp (0001231457) (Filer) | 2026-04-29 | English | ||
| 38550613 | DEF 14A - GENELUX Corp (0001231457) (Filer) | 2026-04-29 | English | ||
| 33052416 | 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | ||
| 33052413 | 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | ||
| 33052411 | 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | ||
| 33052412 | 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | ||
| 32989895 | 424B5 - GENELUX Corp (0001231457) (Filer) | 2026-03-19 | English | ||
| 32989872 | S-8 - GENELUX Corp (0001231457) (Filer) | 2026-03-19 | English | ||
| 32989612 | 8-K - GENELUX Corp (0001231457) (Filer) | 2026-03-19 | English | ||
| 32889064 | 4 - GENELUX CORP (0001231457) (Filer) | 2026-03-04 | English | ||
| 28486065 | 8-K Filing | 2026-02-02 | English | ||
| 28485668 | 8-K Filing | 2026-01-08 | English | ||
| 28485632 | 424B5 Filing | 2026-01-08 | English | ||
| 28485717 | 424B5 Filing | 2026-01-07 | English | ||
| 28485646 | 4 Filing | 2026-01-07 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Abliva
Biopharmaceutical company developing medicines for primary …
|
ABLI | SE | Manufacturing |
|
AB Science
Researches and develops protein kinase inhibitors for human…
|
AB | FR | Manufacturing |
|
ABVC BIOPHARMA, INC.
Develops botanical drugs and medical devices for oncology, …
|
ABVC | US | Manufacturing |
|
ACADIA PHARMACEUTICALS INC
Biopharmaceutical company developing medicines for CNS diso…
|
ACAD | US | Manufacturing |
|
Access Bio, Inc.
Develops and manufactures in vitro diagnostic solutions for…
|
950130 | IN | Manufacturing |
|
Accretion Nutraveda Limited
Develops and manufactures pharmaceutical, nutraceutical, an…
|
544694 | IN | Manufacturing |
|
Accretion Pharmaceuticals Limited
Develops and manufactures therapeutic formulations across d…
|
ACCPL | IN | Manufacturing |
|
Acerus Pharmaceuticals Corporation
Specialty pharmaceutical company focused on developing and …
|
ASPCF | CA | Manufacturing |
|
ACHIEVE LIFE SCIENCES, INC.
A late-stage pharmaceutical company developing a treatment …
|
ACHV | US | Manufacturing |
|
Achyut Healthcare Limited
Procures, trades, and manufactures pharmaceutical APIs and …
|
543499 | IN | Manufacturing |
GENELUX Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33857/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33857 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33857 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33857 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33857}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GENELUX Corp (id: 33857)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.